Luca Issi is ranked #1580 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Luca Issi (RBC Capital) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Luca Issi's stock ratings?

About 38% of Luca's ratings were profitable over a one-year hold, with an average return of +3.2% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Luca Issi

RBC

Luca Issi

RBC Capital

Wall Street Analyst

★★★☆☆

#1580

on 13Foresight · ranked by our own returns

38%

Success Rate

+3.0%

Average Return

11 of 29 calls profitable · -1.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 38% of Luca Issi's ratings turned a profit when each position was held for 1 year — averaging +3.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

110 Buy 57 Hold 0 Sell

Luca's Stock Coverage 29 ratings · 2026-06-18

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
FULC Fulcrum Therapeutics	Jun 02, 2026	HOLD	Hold +151.5% avg upside 13 analysts	$4.00 14.32% Upside	·
ALNY Alnylam Pharma	May 27, 2026	BUY	Strong Buy +22.4% avg upside 51 analysts	$445.00 57.40% Upside	-4.3%
GB:0QW0 arGEN X	May 27, 2026	BUY	Strong Buy -22.6% avg upside 24 analysts	—	·
ARGX Argenx Se	May 27, 2026	BUY	Strong Buy -16.4% avg upside 46 analysts	$890.00 0.21% Downside	+7.5%
SGMO Sangamo Therapeutics	May 14, 2026	HOLD	Buy +5737.2% avg upside 16 analysts	$2.00 1020.44% Upside	-7.1%
RGNX RegenXBio	May 14, 2026	BUY	Strong Buy +374.0% avg upside 22 analysts	$19.00 140.51% Upside	-8.3%
ALLO Allogene Therapeutics	May 13, 2026	BUY	Strong Buy +673.3% avg upside 28 analysts	$9.00 359.09% Upside	-18.4%
LXEO Lexeo Therapeutics, Inc.	May 11, 2026	BUY	Strong Buy +309.3% avg upside 11 analysts	$20.00 301.64% Upside	-16.8%
DYN Dyne Therapeutics	May 11, 2026	BUY	Strong Buy +98.3% avg upside 29 analysts	$30.00 56.22% Upside	+1.5%
NTLA Intellia Therapeutics	May 11, 2026	HOLD	Buy +158.2% avg upside 37 analysts	$15.00 1.35% Downside	-16.0%
BEAM Beam Therapeutics	May 08, 2026	HOLD	Strong Buy +57.5% avg upside 25 analysts	$26.00 20.04% Downside	-9.0%
CRBU Caribou Biosciences	May 08, 2026	BUY	Strong Buy +585.9% avg upside 12 analysts	$10.00 509.82% Upside	+10.3%
KRRO Korro Bio	May 08, 2026	HOLD	Strong Buy +133.8% avg upside 19 analysts	$8.00 27.68% Downside	-8.3%
ASND Ascendis Pharma	May 07, 2026	BUY	Strong Buy +16.5% avg upside 24 analysts	$275.00 18.95% Upside	-9.3%
ARWR Arrowhead Pharmaceuticals	May 07, 2026	BUY	Strong Buy -18.4% avg upside 26 analysts	$87.00 7.30% Upside	-4.4%
BBIO BridgeBio Pharma	May 07, 2026	BUY	Strong Buy +36.6% avg upside 34 analysts	$100.00 48.45% Upside	-0.1%
RARE Ultragenyx Pharmaceutical	May 05, 2026	BUY	Strong Buy +144.1% avg upside 36 analysts	$35.00 30.06% Upside	-7.6%
EDIT Editas Medicine	May 05, 2026	HOLD	Buy +434.5% avg upside 33 analysts	$4.00 56.93% Upside	-13.0%
QURE uniQure	May 05, 2026	BUY	Strong Buy +2.0% avg upside 29 analysts	$35.00 27.31% Downside	+16.8%
CRSP Crispr Therapeutics AG	May 04, 2026	HOLD	Buy +41.5% avg upside 41 analysts	$50.00 5.91% Downside	-2.9%
BMRN BioMarin Pharmaceutical	May 04, 2026	HOLD	Strong Buy +71.7% avg upside 52 analysts	$66.00 20.01% Upside	-0.8%
MRNA Moderna	May 01, 2026	HOLD	Hold +9.4% avg upside 38 analysts	$38.00 38.53% Downside	+12.3%
AMGN Amgen	Apr 30, 2026	BUY	Buy -12.2% avg upside 57 analysts	$370.00 8.32% Upside	+1.2%
AGIO Agios Pharma	Apr 29, 2026	HOLD	Strong Buy +78.4% avg upside 29 analysts	$28.00 15.39% Downside	+0.4%
IONS Ionis Pharmaceuticals	Apr 29, 2026	BUY	Strong Buy +13.0% avg upside 43 analysts	$100.00 34.59% Upside	-2.1%
WVE Wave Life Sciences	Apr 28, 2026	BUY	Strong Buy +272.2% avg upside 28 analysts	$15.00 152.10% Upside	-22.7%
MGTX Meiragtx Holdings	Nov 13, 2024	BUY	Strong Buy +145.6% avg upside 13 analysts	$11.00 5.76% Upside	+17.3%
QTTB Q32 Bio	May 11, 2023	HOLD	Buy +315.2% avg upside 24 analysts	$54.00 318.29% Upside	+51.5%
LENZ LENZ Therapeutics	Mar 21, 2023	HOLD	Buy +280.4% avg upside 17 analysts	$3.00 52.70% Downside	+93.9%

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Luca Issi — Frequently Asked Questions

How accurate are Luca Issi's stock ratings?

Based on the calls 13Foresight could measure, about 38% of Luca's ratings were profitable over a one-year hold, with an average return of +3.2% per rating, or -1.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Luca ranked on 13Foresight?

Luca Issi is currently ranked #1580 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Luca cover?

Luca most recently has ratings on FULC, ALNY, GB:0QW0, ARGX, SGMO, RGNX, ALLO, LXEO, DYN, NTLA, BEAM, CRBU and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!